Daniel Goldstein MD

Founding Director, Center for Cancer Economics, Professor of Oncology @Rabinmedical_. @TelAvivUni.

[Dr Amol Akhade @SuyogCancer]

Happy To Share Our Paper published In Lancet Oncology.
It is joint venture between myself and @ManjuSengar7 and Dr Roni Levin And @drdgoldstein from Israel 🇮🇱.

We closely looked at Subcut IO drugs approvals and discuss that even though sub cut formulations are more convenient they may actually prolong patents and may delay entry of Biosimilar IO drugs .

Wolf 🐺 in Sheep 🐑 clothing.
Classic essay in Pharmaco Economics 🙂
@TheLancetOncol @Larvol @brunolarvol @OncBrothers @MedwatchKate
https://t.co/3AyAAgbmep

[Daniel Goldstein MD @drdgoldstein]

Great work by Robert Langreth from Bloomberg News in reporting our work related to the opportunities of low-dosed immunotherapy.

The concept is increasingly becoming mainstream.

https://t.co/GNUORI8Oir via @business

[Daniel Goldstein MD @drdgoldstein]

@GalMarkel I also express gratitude for the opportunity of the past 4 years working within the headquarters of Clalit, Israel’s largest HMO. It was an unparalleled opportunity to see the inner workings of policy decision making in the health system. Looking forward to this new chapter. end

[Daniel Goldstein MD @drdgoldstein]

Some personal news…. I’m delighted to announce that I’m returning full time to the Davidoff center of Rabin Medical Center. I will be opening the Center for Health Economics and Medical Decision Making, which will focus on Education, Research and Consultancy. 1/n

[Daniel Goldstein MD @drdgoldstein]

I will continue my clinical work as a GU oncologist. I have great thanks to the Director of the Davidoff Center, @GalMarkel, and my long-time colleague and friend Dr Eli Rosenbaum who have provided great support in making this happen, and who share and appreciate the vision. 2/n

[Daniel Goldstein MD @drdgoldstein]

Our new paper - the tyranny of non-inferiority.

[Dr Amol Akhade @SuyogCancer]

The tyranny of Non -inferiority Trials. Excellent view 👌 by @ian_tannock @drdgoldstein @TheLancetOncol

[Massimo Di Maio @MassimoDiMaio75]

With my friends @oncology_bg @drdgoldstein #ESMO24

[Daniel Goldstein MD @drdgoldstein]

Vote for Chris - he definitely gets my full support!

[Prof. Chris Jackson @drkiwicj]

Honoured to be standing for @uicc Board of Directors.

Fewer cancers, better survival, fairer access to care through collaboration and partnership, is why I am standing.

See my FB post for more info: https://t.co/xOInn0ZAYS

#UICC #CancerEquity #BetterFairerCancerCare

[Daniel Goldstein MD @drdgoldstein]

Our new paper about overuse of PETCT using real world data from Clalit in Israel.

[BMJ Oncology @BMJOncology]

📣 Choosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancer

Check out this #originalresearch from @drdgoldstein and colleagues: https://t.co/LzwoL7BUjt

#oncoalert @oncoalert

[Daniel Goldstein MD @drdgoldstein]

https://t.co/R13tcUipaK

[Daniel Goldstein MD @drdgoldstein]

Really great pleasure to help to run this workshop in Hong Kong. Thanks to Vivian Lee for amazing organization, and to @herbloong for being a great host to satisfy my foodie instincts!

[Herbert Loong, MBBS, FASCO @herbloong]

Thanks @drdgoldstein for coming all the way from 🇮🇱 to 🇭🇰 to share insights and experiences in #pharmacoeconomics. Organised by #ProfVivianLee and colleagues of @cuhkpharmacy Very engaged workshop together with stakeholders from #academia, #industry, #patientsrepresentatives and the #HospitalAuthority @CUHKMedicine @hkumed

[Common Sense Oncology @csoncol]

Thank you @TheLancetOncol for the shout out to Common Sense Oncology movement in the latest editorial. The editorial is excellent and open access. We highly encourage you to read it in its entirety.

https://t.co/WhQGuhIlLe

[Daniel Goldstein MD @drdgoldstein]

US Senator now getting involved in cancer drug dosing issues

[Senator Dick Durbin @SenatorDurbin]

NEWS: I sent a letter to Amgen to investigate the pharma co’s decisions on its cancer drug—after FDA review & new studies suggest its dosing level may be excessive, exposing cancer patients to unnecessarily high costs & harsh side effects from the company’s 8-pill daily dosage.

[Daniel Goldstein MD @drdgoldstein]

Totally love this. I’m proud to be an “old-fashioned” doctor!

[Adam Cifu @adamcifu]

Totally flattered by all who tagged me when they shared this piece. As @VPrasadMDMPH said, I wish I had written it.

[Bishal Gyawali, MD, PhD, FASCO @oncology_bg]

Join us by Zoom for the first open plenary session of @csoncol . Register here- https://t.co/ywEXlvTby1

[GU Oncology Now @GUOncologyNow]

🎧 Catch the latest episode of the @Uromigos (@brian_rini, @tompowles1) with @drdgoldstein on dosing issues and dosing changes in drugs such as #nivolumab and #pembrolizumab, as well as other immune checkpoint inhibitors.

👂 Listen Here: https://t.co/ttuO4Qi0tZ

[Dr Deme Karikios @DKarikios]

If you are an oncologist/trainee interested in the Common Sense Oncology movement you can contribute here @csoncol #commonsenseoncology:

[Daniel Goldstein MD @drdgoldstein]

@ajumathew_ Hey Aju. The issue of CDK4/6 is complex and nuanced. There is definitely opportunity for class effect exploitation, but not in the adjuvant setting. I would argue that the data are weak to support any cdk4/6 in the adjuvant setting. https://t.co/qPbsjyyPwr

[Daniel Goldstein MD @drdgoldstein]

Our new paper on class effects in oncology. A great opportunity for savings for health care payers, without impacting outcomes.

[BMJ Oncology @BMJOncology]

A new review suggests that many cancer drugs are interchangeable, which could potentially lead to significant cost savings for patients and health systems.

@drdgoldstein

https://t.co/crBe65cmdA